Lost in (Clinical) Translation: Recent Advances in Heparin Neutralization and Monitoring.
Journal
ACS chemical biology
ISSN: 1554-8937
Titre abrégé: ACS Chem Biol
Pays: United States
ID NLM: 101282906
Informations de publication
Date de publication:
20 12 2019
20 12 2019
Historique:
pubmed:
5
11
2019
medline:
3
4
2020
entrez:
5
11
2019
Statut:
ppublish
Résumé
The heparin family, which includes unfractionated heparin, low-molecular heparin, and fondaparinux, is a class of drugs clinically used as intravenous blood thinners. To date, issues related to both the reversal of anticoagulation and the blood level determination of the anticoagulant at the point-of-care remain: while the only U.S. Food and Drug Administration (FDA) approved antidote for heparin displays serious efficacy and safety drawbacks, the current assays for heparin monitoring are indirect measurements subject to their own limitations and variations. Herein, we provide an update on the numerous recent chemical approaches to tackle these issues, from which it is clear that some new antidotes and sensors for heparin certainly have the potential to exceed current clinical standards. This review aims to review a field that requires close collaborations between physicians, biologists, and chemists in order to foster advances toward clinical translation.
Identifiants
pubmed: 31682398
doi: 10.1021/acschembio.9b00772
doi:
Substances chimiques
Anticoagulants
0
Metals
0
Polymers
0
Heparin
9005-49-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM